Common treatment for ITP with a presumed mechanism of action of involving selective RBC destruction, so should be used with caution in patients with anemia.
Can cause intravascular hemolysis and rarely renal insufficiency.
Leads to hemolysis, with a drop in hemoglobin of approximately 1 g/dL and a much more significant drop in patients with pre-existing red cell antibodies.
Use in patients with positive direct anti-globulin test (Coombs test) is contraindicated.